#SFHS2608155AOrder of April 8, 2026, modifying the list of pharmaceutical specialties approved for use by communities and various public services
AI-generated summary for informational purposes only. Not legal advice. See the original source for the authoritative text.
This law updates the list of medicines approved for use by public health institutions in France. Specific epilepsy medications and osteoporosis treatments have been added, impacting hospitals and clinics that rely on insurance coverage for these drugs. This means healthcare providers may need to update their procurement lists and adjust treatment options accordingly.
AI-generated summary. May contain errors. Refer to official sources for legal decisions.
Key Changes
- Added epilepsy medications to the approved list
- Included specific osteoporosis treatments
- Public health institutions must check new insurance coverage
Obligations
What this law requires
Healthcare institutions must update their pharmaceutical procurement lists to include Brivaracetam Zentiva (25mg, 50mg, 75mg, 100mg) for approved use in treating partial seizures in adults and adolescents aged 16+ and children aged 2-15 with epilepsy
Healthcare institutions must update their pharmaceutical procurement lists to include Fampridine Sandoz LP and Fampridine Zentiva LP (10mg) in approved presentations for use in public health services
Healthcare institutions must update their pharmaceutical procurement lists to include Furosemide Teva Santé (500mg) for use in public health services
Healthcare institutions must update their pharmaceutical procurement lists to include Zolestad (5mg/100ml zoledronic acid) for approved osteoporosis treatment indications including post-menopausal osteoporosis, male osteoporosis, corticosteroid-induced osteoporosis, and Paget's disease
Insurance coverage for Brivaracetam Zentiva must be limited to treatment of partial seizures with or without secondary generalization in specified age groups (adults/adolescents 16+ and children 2-15) with epilepsy